Back

Rezera's Phase 2 RESOLVE-1 trial selected for AHA Featured Science

Verifying
  • Rezera announced RESOLVE-1's selection for a late-breaking AHA Featured Science presentation.
  • The presentation is scheduled for November 7, 2026, from 3:15 p.m. to 4:30 p.m. CT.
  • Rezera said RESOLVE-1 met its primary inflammation endpoint with a favorable safety profile.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.